These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22145122)

  • 1. Quality of clinical trials: A moving target.
    Bhatt A
    Perspect Clin Res; 2011 Oct; 2(4):124-8. PubMed ID: 22145122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good clinical practice regulatory inspections: Lessons for Indian investigator sites.
    Marwah R; Van de Voorde K; Parchman J
    Perspect Clin Res; 2010 Oct; 1(4):151-5. PubMed ID: 21350732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GCP inspections in Germany and Europe following the implementation of the Directive 2001/20/EC.
    Göbel C; Baier D; Ruhfus B; Hundt F
    Ger Med Sci; 2009 Mar; 7():Doc01. PubMed ID: 19675741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US food and drug administration Indian site inspections: An experience.
    Mahajan P; D'Souza N; Bhatt A; Halbe V; Sharma R; Narayanswamy S; Bughediwala M
    Perspect Clin Res; 2012 Apr; 3(2):73-9. PubMed ID: 22701824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world.
    Caldron PH; Gavrilova SI; Kropf S
    Drug Des Devel Ther; 2012; 6():53-60. PubMed ID: 22563236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
    Jung M; Swann RM; Anantha MS; Jamali F
    Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigator Responsibilities in Clinical Research.
    Feehan AK; Garcia-Diaz J
    Ochsner J; 2020; 20(1):44-49. PubMed ID: 32284682
    [No Abstract]   [Full Text] [Related]  

  • 14. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
    Morgan-Linnell SK; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raising suspicions with the Food and Drug Administration: detecting misconduct.
    Hamrell MR
    Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA; Epnere K; Bhansali N
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of contract research organizations in translational medicine.
    Shih MS
    J Orthop Translat; 2015 Apr; 3(2):85-88. PubMed ID: 30035044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.